O	0	11	Sensitivity
O	12	15	and
O	16	27	specificity
O	28	30	of
B-intervention	31	42	mammography
I-intervention	43	46	and
I-intervention	47	57	adjunctive
I-intervention	58	73	ultrasonography
O	74	76	to
O	77	83	screen
O	84	87	for
O	88	94	breast
O	95	101	cancer
O	102	104	in
O	105	108	the
B-location	109	114	Japan
O	115	124	Strategic
O	125	129	Anti
O	129	130	-
O	130	136	cancer
O	137	147	Randomized
O	148	153	Trial
O	154	155	(
O	155	156	J
O	156	157	-
O	157	162	START
O	162	163	)
O	163	164	:
O	165	166	a
O	167	177	randomised
O	178	188	controlled
O	189	194	trial
O	194	195	.

O	196	207	Mammography
O	208	210	is
O	211	214	the
O	215	219	only
O	220	226	proven
O	227	233	method
O	234	237	for
O	238	244	breast
O	245	251	cancer
O	252	261	screening
O	262	266	that
O	267	274	reduces
O	275	284	mortality
O	284	285	,
O	286	294	although
O	295	297	it
O	298	300	is
O	301	311	inaccurate
O	312	314	in
O	315	320	young
O	321	326	women
O	327	329	or
O	330	335	women
O	336	340	with
O	341	346	dense
O	347	354	breasts
O	354	355	.

O	356	358	We
O	359	371	investigated
O	372	375	the
O	376	384	efficacy
O	385	387	of
O	388	398	adjunctive
O	399	414	ultrasonography
O	414	415	.

O	416	423	Between
O	424	428	July
O	428	429	,
O	430	434	2007
O	434	435	,
O	436	439	and
O	440	445	March
O	445	446	,
O	447	451	2011
O	451	452	,
O	453	455	we
O	456	464	enrolled
O	465	477	asymptomatic
O	478	483	women
O	484	488	aged
B-age	489	491	40
I-age	491	492	-
I-age	492	494	49
I-age	495	500	years
O	501	503	at
O	504	506	42
O	507	512	study
O	513	518	sites
O	519	521	in
O	522	524	23
O	525	536	prefectures
O	537	541	into
O	542	545	the
O	546	551	Japan
O	552	561	Strategic
O	562	566	Anti
O	566	567	-
O	567	573	cancer
O	574	584	Randomized
O	585	590	Trial
O	591	592	(
O	592	593	J
O	593	594	-
O	594	599	START
O	599	600	)
O	600	601	.

O	602	610	Eligible
O	611	616	women
O	617	620	had
B-eligibility	621	623	no
I-eligibility	624	631	history
I-eligibility	632	634	of
I-eligibility	635	638	any
I-eligibility	639	645	cancer
I-eligibility	646	648	in
I-eligibility	649	652	the
I-eligibility	653	661	previous
I-eligibility	662	663	5
I-eligibility	664	669	years
I-eligibility	670	673	and
I-eligibility	674	678	were
I-eligibility	679	687	expected
I-eligibility	688	690	to
I-eligibility	691	695	live
I-eligibility	696	699	for
I-eligibility	700	704	more
I-eligibility	705	709	than
I-eligibility	710	711	5
I-eligibility	712	717	years
O	717	718	.

O	719	732	Randomisation
O	733	736	was
O	737	741	done
O	742	751	centrally
O	752	754	by
O	755	758	the
O	759	764	Japan
O	765	773	Clinical
O	774	782	Research
O	783	790	Support
O	791	795	Unit
O	795	796	.

O	797	809	Participants
O	810	814	were
O	815	823	randomly
O	824	832	assigned
O	833	835	in
O	836	837	1
O	837	838	:
O	838	839	1
O	840	845	ratio
O	846	848	to
O	849	856	undergo
O	857	868	mammography
O	869	872	and
O	873	888	ultrasonography
O	889	890	(
O	890	902	intervention
O	903	908	group
O	908	909	)
O	910	912	or
B-control	913	924	mammography
I-control	925	930	alone
I-control	931	932	(
I-control	932	939	control
I-control	940	945	group
I-control	945	946	)
O	947	952	twice
O	953	955	in
O	956	957	2
O	958	963	years
O	963	964	.

O	965	968	The
O	969	976	primary
O	977	984	outcome
O	985	988	was
B-outcome-Measure	989	1000	sensitivity
O	1000	1001	,
B-outcome-Measure	1002	1013	specificity
O	1013	1014	,
B-outcome-Measure	1015	1021	cancer
I-outcome-Measure	1022	1031	detection
I-outcome-Measure	1032	1036	rate
O	1036	1037	,
O	1038	1041	and
B-outcome-Measure	1042	1047	stage
I-outcome-Measure	1048	1060	distribution
O	1061	1063	at
O	1064	1067	the
O	1068	1073	first
O	1074	1079	round
O	1080	1082	of
O	1083	1092	screening
O	1092	1093	.

O	1094	1102	Analysis
O	1103	1106	was
O	1107	1109	by
O	1110	1119	intention
O	1120	1122	to
O	1123	1128	treat
O	1128	1129	.

O	1130	1134	This
O	1135	1140	study
O	1141	1143	is
O	1144	1154	registered
O	1154	1155	,
O	1156	1162	number
O	1163	1176	UMIN000000757
O	1176	1177	.

O	1178	1180	Of
B-total-participants	1181	1183	72
I-total-participants	1183	1184	,
I-total-participants	1184	1187	998
O	1188	1193	women
O	1194	1202	enrolled
O	1202	1203	,
B-intervention-participants	1204	1206	36
I-intervention-participants	1206	1207	,
I-intervention-participants	1207	1210	859
O	1211	1215	were
O	1216	1224	assigned
O	1225	1227	to
O	1228	1231	the
O	1232	1244	intervention
O	1245	1250	group
O	1251	1254	and
B-control-participants	1255	1257	36
I-control-participants	1257	1258	,
I-control-participants	1258	1261	139
O	1262	1264	to
O	1265	1268	the
O	1269	1276	control
O	1277	1282	group
O	1282	1283	.

B-outcome	1284	1295	Sensitivity
O	1296	1299	was
O	1300	1313	significantly
O	1314	1320	higher
O	1321	1323	in
O	1324	1327	the
O	1328	1340	intervention
O	1341	1346	group
O	1347	1351	than
O	1352	1354	in
O	1355	1358	the
O	1359	1366	control
O	1367	1372	group
O	1373	1374	(
B-iv-bin-percent	1374	1376	91
I-iv-bin-percent	1376	1377	·
I-iv-bin-percent	1377	1378	1
I-iv-bin-percent	1378	1379	%
O	1379	1380	,
O	1381	1383	95
O	1383	1384	%
O	1385	1387	CI
O	1388	1390	87
O	1390	1391	·
O	1391	1392	2
O	1392	1393	-
O	1393	1395	95
O	1395	1396	·
O	1396	1397	0
O	1398	1400	vs
B-cv-bin-percent	1401	1403	77
I-cv-bin-percent	1403	1404	·
I-cv-bin-percent	1404	1405	0
I-cv-bin-percent	1405	1406	%
O	1406	1407	,
O	1408	1410	70
O	1410	1411	·
O	1411	1412	3
O	1412	1413	-
O	1413	1415	83
O	1415	1416	·
O	1416	1417	7
O	1417	1418	;
O	1419	1420	p
O	1420	1421	=
O	1421	1422	0
O	1422	1423	·
O	1423	1427	0004
O	1427	1428	)
O	1428	1429	,
O	1430	1437	whereas
B-outcome	1438	1449	specificity
O	1450	1453	was
O	1454	1467	significantly
O	1468	1473	lower
O	1474	1475	(
B-iv-bin-percent	1475	1477	87
I-iv-bin-percent	1477	1478	·
I-iv-bin-percent	1478	1479	7
I-iv-bin-percent	1479	1480	%
O	1480	1481	,
O	1482	1484	87
O	1484	1485	·
O	1485	1486	3
O	1486	1487	-
O	1487	1489	88
O	1489	1490	·
O	1490	1491	0
O	1492	1494	vs
B-cv-bin-percent	1495	1497	91
I-cv-bin-percent	1497	1498	·
I-cv-bin-percent	1498	1499	4
I-cv-bin-percent	1499	1500	%
O	1500	1501	,
O	1502	1504	91
O	1504	1505	·
O	1505	1506	1
O	1506	1507	-
O	1507	1509	91
O	1509	1510	·
O	1510	1511	7
O	1511	1512	;
O	1513	1514	p
O	1514	1515	<
O	1515	1516	0
O	1516	1517	·
O	1517	1521	0001
O	1521	1522	)
O	1522	1523	.

O	1524	1528	More
B-outcome	1529	1536	cancers
O	1537	1541	were
O	1542	1550	detected
O	1551	1553	in
O	1554	1557	the
O	1558	1570	intervention
O	1571	1576	group
O	1577	1581	than
O	1582	1584	in
O	1585	1588	the
O	1589	1596	control
O	1597	1602	group
O	1603	1604	(
B-iv-bin-abs	1604	1607	184
O	1608	1609	[
B-iv-bin-percent	1609	1610	0
I-iv-bin-percent	1610	1611	·
I-iv-bin-percent	1611	1613	50
I-iv-bin-percent	1613	1614	%
I-iv-bin-percent	1614	1615	]
O	1616	1618	vs
B-cv-bin-abs	1619	1622	117
O	1623	1624	[
B-cv-bin-percent	1624	1625	0
I-cv-bin-percent	1625	1626	·
I-cv-bin-percent	1626	1628	32
I-cv-bin-percent	1628	1629	%
O	1629	1630	]
O	1630	1631	,
O	1632	1633	p
O	1633	1634	=
O	1634	1635	0
O	1635	1636	·
O	1636	1640	0003
O	1640	1641	)
O	1642	1645	and
O	1646	1650	were
O	1651	1655	more
O	1656	1666	frequently
B-outcome	1667	1672	stage
I-outcome	1673	1674	0
I-outcome	1675	1678	and
I-outcome	1679	1680	I
O	1681	1682	(
B-iv-bin-abs	1682	1685	144
O	1686	1687	[
B-iv-bin-percent	1687	1689	71
I-iv-bin-percent	1689	1690	·
I-iv-bin-percent	1690	1691	3
I-iv-bin-percent	1691	1692	%
O	1692	1693	]
O	1694	1696	vs
B-cv-bin-abs	1697	1699	79
O	1700	1701	[
B-cv-bin-percent	1701	1703	52
I-cv-bin-percent	1703	1704	·
I-cv-bin-percent	1704	1705	0
I-cv-bin-percent	1705	1706	%
O	1706	1707	]
O	1707	1708	,
O	1709	1710	p
O	1710	1711	=
O	1711	1712	0
O	1712	1713	·
O	1713	1717	0194
O	1717	1718	)
O	1718	1719	.

B-iv-bin-abs	1720	1722	18
O	1723	1724	(
B-iv-bin-percent	1724	1725	0
I-iv-bin-percent	1725	1726	·
I-iv-bin-percent	1726	1728	05
I-iv-bin-percent	1728	1729	%
O	1729	1730	)
B-outcome	1731	1739	interval
I-outcome	1740	1747	cancers
O	1748	1752	were
O	1753	1761	detected
O	1762	1764	in
O	1765	1768	the
O	1769	1781	intervention
O	1782	1787	group
O	1788	1796	compared
O	1797	1801	with
B-cv-bin-abs	1802	1804	35
O	1805	1806	(
B-cv-bin-percent	1806	1807	0
I-cv-bin-percent	1807	1808	·
I-cv-bin-percent	1808	1810	10
I-cv-bin-percent	1810	1811	%
O	1811	1812	)
O	1813	1815	in
O	1816	1819	the
O	1820	1827	control
O	1828	1833	group
O	1834	1835	(
O	1835	1836	p
O	1836	1837	=
O	1837	1838	0
O	1838	1839	·
O	1839	1842	034
O	1842	1843	)
O	1843	1844	.

O	1845	1855	Adjunctive
O	1856	1871	ultrasonography
O	1872	1881	increases
O	1882	1893	sensitivity
O	1894	1897	and
O	1898	1907	detection
O	1908	1912	rate
O	1913	1915	of
O	1916	1921	early
O	1922	1929	cancers
O	1929	1930	.

O	1931	1939	Ministry
O	1940	1942	of
O	1943	1949	Health
O	1949	1950	,
O	1951	1957	Labour
O	1958	1961	and
O	1962	1969	Welfare
O	1970	1972	of
O	1973	1978	Japan
O	1978	1979	.
